Baseline demographics and clinical characteristics of 3,956 rosuvastatin-treated patients Donald G. Vidt, et al. Am J Cardiol 2006;97:1602–1606.

Slides:

Advertisements

Similar presentations

Sibbing D, et al. J Am Coll Cardiol 2009;53:

Advertisements

CE-1 CRESTOR ® Clinical Development Efficacy James W. Blasetto, MD, MPH Senior Director, Clinical Research.

Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose? Systolic.

Patient disposition Dichtl W, et al. Am J Cardiol. 2008;102:743-8 AVR = aortic valve replacement; MDCT = multidetector computed tomographic.

Background There are 12 different types of medications to lower blood sugar levels in patients with type 2 diabetes. It is widely agreed upon that metformin.

ALLHAT 6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (3 GROUPS by GFR)

Hsia J et al. J Am Coll Cardiol 2011;57: Baseline Characteristics by Treatment Group and Attained LDL-C Hsia J et al. J Am Coll Cardiol 2011;57:

ACE inhibitors, ARBs and Statins in COPD: High- and Low-Risk Cohorts G. B. John Mancini, et al. J Am Coll Cardiol 2006;47:

Flow of Patients Through the Trial Nissen SE, et al. JAMA 2008;299:

6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (4 GROUPS by GFR) ALLHAT.

Trial profile Mann JF et al. Lancet 2008;372:

Date of download: 5/29/2016 Copyright © The American College of Cardiology. All rights reserved. From: Impact of Renal Denervation on 24-Hour Ambulatory.

Date of download: 6/18/2016 Copyright © The American College of Cardiology. All rights reserved. From: Efficacy and Safety of Fasudil in Patients With.

Date of download: 9/19/2016 Copyright © The American College of Cardiology. All rights reserved. From: What resting heart rate should one aim for when.

Copyright © 2003 American Medical Association. All rights reserved.

Volume 83, Issue 2, Pages (February 2013)

H. Mansell, L.J. Worobetz, T. Sylwestrowicz, A.S. Shoker

Impact of Age and Estimated Glomerular Filtration Rate on the Glycemic Efficacy and Safety of Canagliflozin: A Pooled Analysis of Clinical Studies Richard.

Baseline Demographic and Clinic Variables According to Office vs 24-Hour or Home BP Giuseppe Mancia, et al. Hypertension 2006;47;

Baseline Characteristics of the Patients Part I

Daniel J. Lenihan et al. BTS 2016;1:

by Clarisse Toledo, George Thomas, Jesse D

Volume 93, Issue 6, Pages (June 2018)

Volume 386, Issue 10008, Pages (November 2015)

Fan et al. Am J Nephrol 2017;45: (DOI: / )

Clinical Trial of Vadadustat in Patients with Anemia Secondary to Stage 3 or 4 Chronic Kidney Disease Martin et al. Am J Nephrol 2017;45: (DOI:

Effect of evolocumab on lipoprotein particles

Figure 3 Ischaemic outcomes in the ST-segment elevation myocardial

ACR20, ACR50, and ACR70 response rates during the 12-week study of Japanese patients with rheumatoid arthritis treated with baricitinib or placebo. ACR20,

Ventilatory and cerebrovascular responses to hyperoxic hypercapnia.

Figure 2 Ischaemic and bleeding outcomes in the major clinical trials

Pharmacodynamic Effects of Sucroferric Oxyhydroxide and Sevelamer Carbonate on Vitamin D Receptor Agonist Bioactivity in Dialysis Patients Sprague et al.

A: Kaplan-Meier estimate of time to first LLA

Volume 93, Issue 1, Pages (January 2018)

A comparison of efficacy and safety of 2-year telbivudine and entecavir treatment in patients with chronic hepatitis B: a match–control study M.-C. Tsai,

Volume 88, Issue 2, Pages (August 2015)

TACTICS-HF Trial design: Patients with acute heart failure (reduced or preserved ejection fraction) were randomized to tolvaptan 30 mg at 0, 24, and 48.

Nat. Rev. Cardiol. doi: /nrcardio

Erratum American Journal of Kidney Diseases

Patient characteristics in the entire study group

Volume 386, Issue 10008, Pages (November 2015)

Subgroup analysis. Subgroup analysis. Effect of vitamin D supplementation on outcome variables in subgroups defined by baseline levels of the respective.

Flow of Patients Through the Trial

Baseline Characteristics of the Patients and Use of Concomitant Medications – Part I Kaare Harald Bønaa, et al. N Engl J Med 2006;354:

Baseline Patients with coronary artery disease (CAD) and high (n=98) versus normal (n=1512) high-density lipoprotein (HDL) levels Doreen DeFaria Yeh, et.

Baseline Clinical Characteristics

Baseline characteristics for patients with diabetes in ASCOT-LLA Part I P.S. SEVER et al Diabetes Care 2005; 28: 1151–1157.

(A) 1-year mortality in relation to estimated glomerular filtration rate (eGFR), age (n=47 636) and presence of diabetes mellitus (n=47 624). (A) 1-year.

Patient Disposition James A. de Lemos et al. JAMA 2004; 292:

Nowak et al. Am J Nephrol 2016;44: (DOI: / )

Three outcome measures from the NINDS tPA trial

Participation in Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial Hisao Ogawa et al. JAMA 2008;300:

Methods for guideline development

Entry, Randomization, and Follow-up of Patients in the Hypertension in the Very Elderly Trial Of the 461 patients who did not meet the protocol criteria,

Baseline Characteristics by hs-CRP

Figure 3 Clinical and MRI outcomes by quartiles of increasing CD56bright natural killer (NK) cell countsAll data are mean and upper 95% confidence interval.

(A) Mortality in patients with heart failure and different estimated glomerular filtration rate (eGFR) strata, crude survival assessed by Kaplan-Meier.

(G) Body mass index (BMI) values at baseline and after treatment with anagliptin in 20 participants at 12 and 24 weeks. (G) Body mass index (BMI) values.

Absolute mortality difference Change in LVEF from baseline

Inhaled β2 -agonists and airway responses to allergen

Changes of (A) glycated haemoglobin (HbA1c) and (B) estimated glomerular filtration rate (eGFR) in the blood test at baseline and at 3, 6 and 12 months.

Illustration of a trial design to help evaluate the clinical accuracy of a test of ischaemia. Illustration of a trial design to help evaluate the clinical.

Baseline characteristics of study population

Demographic Characteristics of Patients Treated With Statins Versus Those Not Treated With Statins Goldberger JJ, et al. J Am Coll Cardiol 2006;48:

Serum bicarbonate increased by ≥3, ≥4, and ≥5 mEq/L in 52%, 39%, and 22% of patients, respectively, in the combined TRC101 dose group compared with 6%,

The odds ratio comparing phonation to the breath-hold technique is given above the glottis, at the glottis, and below the glottis. The odds ratio comparing.

Effect of methylprednisolone versus placebo on the risk of acute kidney injury: subgroup analysis by preoperative chronic kidney disease. Effect of methylprednisolone.

Fistula and Survival Outcomes after Fistula Creation among Predialysis Chronic Kidney Disease Stage 5 Patients Miyamoto et al. Am J Nephrol 2017;45:

ACR20 (A), ACR50 (B) and MDA (C) response rates at 24 weeks in patients treated with PBO, IXEQ4W or IXEQ2W alone or when added to background cDMARDs or.

Changes of major clinical and biochemical characteristics at baseline and during follow-up in different groups. Changes of major clinical and biochemical.

Presentation transcript:

Baseline demographics and clinical characteristics of 3,956 rosuvastatin-treated patients Donald G. Vidt, et al. Am J Cardiol 2006;97:1602–1606

Mean changes in eGFR (bars) with 95% confidence intervals (whiskers) for each rosuvastatin dose Numbers across the bottom represent the patient number for each dose group; *p<0.01 versus baseline Donald G. Vidt, et al. Am J Cardiol 2006;97:1602–1606

Baseline demographic and clinical characteristics for placebo-controlled trials Donald G. Vidt, et al. Am J Cardiol 2006;97:1602–1606

Change in estimated glomerular filtration rate by subgroups Donald G. Vidt, et al. Am J Cardiol 2006;97:1602–1606